Preparing for Health Care Reform: Why Big Pharma Thinks it Can Avoid Another "Hillarycare"
This article was originally published in RPM Report
Should a Democrat take the White House next January, top pharmaceutical executives expect a serious push for health care reform. The prospect of a health care reform debate triggers the specter of a single-payor, government-run system with price controls. But Democrats are singing a surprisingly soothing tune.
You may also be interested in...
“Project Indy” offers a joint manufacturer/payor perspective on how to enable value based pricing. It also sounds like a potential proposal to CMS to volunteer for a pilot project.
Former HHS general counsel Dan Meron, now a partner at Latham & Watkins, was asked to make predictions on how the Obama Administration would differ from the Bush Administration in a recent speech to the annual meeting of the Food, Drug and Cosmetic Law Section of the New York Bar Association. His remarks were edited for continuity.
In a speech before the Food and Drug Law Institute's conference on collaboration between CMS and FDA, Tom Scully, with his usual candor and humor, gave his views on what the outcome of the national elections could mean to the health care industry and on some of the proposals being floated in Washington. Below are some excerpts from his presentation on Nov. 18 in Washington, D.C. Scully served as CMS administrator from 2001 to 2003. He currently divides his time between the law firm Alston & Bird, where he is senior counsel, and the private equity firm Welsh, Carson, Anderson & Stowe, where he is a general partner.